HKMPY
Price
$49.65
Change
+$1.38 (+2.86%)
Updated
Aug 27 closing price
Capitalization
5.43B
HROW
Price
$39.00
Change
+$0.01 (+0.03%)
Updated
Aug 29 closing price
Capitalization
1.44B
79 days until earnings call
Interact to see
Advertisement

HKMPY vs HROW

Header iconHKMPY vs HROW Comparison
Open Charts HKMPY vs HROWBanner chart's image
Hikma Pharmaceuticals
Price$49.65
Change+$1.38 (+2.86%)
Volume$319
Capitalization5.43B
Harrow
Price$39.00
Change+$0.01 (+0.03%)
Volume$349.3K
Capitalization1.44B
HKMPY vs HROW Comparison Chart in %
Loading...
HKMPY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HKMPY vs. HROW commentary
Aug 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HKMPY is a Hold and HROW is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 30, 2025
Stock price -- (HKMPY: $49.65 vs. HROW: $39.00)
Brand notoriety: HKMPY and HROW are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HKMPY: 75% vs. HROW: 65%
Market capitalization -- HKMPY: $5.43B vs. HROW: $1.44B
HKMPY [@Pharmaceuticals: Generic] is valued at $5.43B. HROW’s [@Pharmaceuticals: Generic] market capitalization is $1.44B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HKMPY’s FA Score shows that 1 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • HKMPY’s FA Score: 1 green, 4 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than HKMPY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HKMPY’s TA Score shows that 5 TA indicator(s) are bullish while HROW’s TA Score has 6 bullish TA indicator(s).

  • HKMPY’s TA Score: 5 bullish, 2 bearish.
  • HROW’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, HKMPY is a better buy in the short-term than HROW.

Price Growth

HKMPY (@Pharmaceuticals: Generic) experienced а +2.85% price change this week, while HROW (@Pharmaceuticals: Generic) price change was -0.31% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.55%. For the same industry, the average monthly price growth was +67.47%, and the average quarterly price growth was +80.21%.

Reported Earning Dates

HROW is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.55% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HKMPY($5.43B) has a higher market cap than HROW($1.44B). HROW YTD gains are higher at: 16.244 vs. HKMPY (2.597). HKMPY has higher annual earnings (EBITDA): 734M vs. HROW (32.1M). HKMPY has more cash in the bank: 127M vs. HROW (53M). HROW has less debt than HKMPY: HROW (231M) vs HKMPY (1.31B). HKMPY has higher revenues than HROW: HKMPY (3.22B) vs HROW (228M).
HKMPYHROWHKMPY / HROW
Capitalization5.43B1.44B376%
EBITDA734M32.1M2,287%
Gain YTD2.59716.24416%
P/E Ratio14.86N/A-
Revenue3.22B228M1,411%
Total Cash127M53M240%
Total Debt1.31B231M565%
FUNDAMENTALS RATINGS
HKMPY vs HROW: Fundamental Ratings
HKMPY
HROW
OUTLOOK RATING
1..100
2819
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
84
Overvalued
PROFIT vs RISK RATING
1..100
9947
SMR RATING
1..100
7895
PRICE GROWTH RATING
1..100
7841
P/E GROWTH RATING
1..100
9511
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HKMPY's Valuation (10) in the null industry is significantly better than the same rating for HROW (84) in the Pharmaceuticals Other industry. This means that HKMPY’s stock grew significantly faster than HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (47) in the Pharmaceuticals Other industry is somewhat better than the same rating for HKMPY (99) in the null industry. This means that HROW’s stock grew somewhat faster than HKMPY’s over the last 12 months.

HKMPY's SMR Rating (78) in the null industry is in the same range as HROW (95) in the Pharmaceuticals Other industry. This means that HKMPY’s stock grew similarly to HROW’s over the last 12 months.

HROW's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for HKMPY (78) in the null industry. This means that HROW’s stock grew somewhat faster than HKMPY’s over the last 12 months.

HROW's P/E Growth Rating (11) in the Pharmaceuticals Other industry is significantly better than the same rating for HKMPY (95) in the null industry. This means that HROW’s stock grew significantly faster than HKMPY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HKMPYHROW
RSI
ODDS (%)
Bullish Trend 1 day ago
59%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
54%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
47%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
59%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
55%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
N/A
Bearish Trend 12 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
31%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
67%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
HKMPY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USLIX75.60N/A
N/A
JHancock U.S. Global Leaders Growth I
GSAEX26.38N/A
N/A
Goldman Sachs China Equity Inv
JVAQX40.56N/A
N/A
JPMorgan Value Advantage R4
GQHPX13.34N/A
N/A
GQG Partners US Quality Value Fund Inv
IARIX16.84N/A
N/A
Invesco Real Estate R5

HKMPY and

Correlation & Price change

A.I.dvisor tells us that HKMPY and HROW have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HKMPY and HROW's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HKMPY
1D Price
Change %
HKMPY100%
N/A
HROW - HKMPY
23%
Poorly correlated
+0.03%
CXXIF - HKMPY
22%
Poorly correlated
-3.82%
HYPMY - HKMPY
14%
Poorly correlated
-5.15%
ETST - HKMPY
10%
Poorly correlated
N/A
INDV - HKMPY
8%
Poorly correlated
+1.68%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with OGI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then OGI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+0.03%
OGI - HROW
34%
Loosely correlated
N/A
AQST - HROW
33%
Loosely correlated
-1.57%
TKNO - HROW
31%
Poorly correlated
+0.23%
AMRX - HROW
31%
Poorly correlated
+0.10%
VTRS - HROW
30%
Poorly correlated
+1.34%
More